News >

Olaparib/Neratinib Combo Highly Synergistic in HER2+ Uterine Serous Carcinoma

Kristi Rosa
Published: Monday, Apr 15, 2019

Ghanshyam Yadav, MD

Ghanshyam Yadav, MD

The combination of the PARP inhibitor olaparib (Lynparza) and the pan-HER TKI neratinib (Nerlynx) proved to be highly synergistic and demonstrated significant activity in preclinical models of HER2-positive uterine serous carcinoma.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x